Cargando…
Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients
INTRODUCTION: Booster doses of SARS-CoV-2 vaccines improve seroconversion rates in solid organ transplant recipients (SOTRs) but the impact of homologous and heterologous booster doses in neutralizing antibody (NAb) titers and their ability to interfere with the variant of concern Omicron are not we...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044136/ https://www.ncbi.nlm.nih.gov/pubmed/36999018 http://dx.doi.org/10.3389/fimmu.2023.1135478 |
_version_ | 1784913300253835264 |
---|---|
author | Gaete-Argel, Aracelly Saavedra-Alarcón, Vicente Sauré, Denis Alonso-Palomares, Luis Acevedo, Mónica L. Alarcón, Marion Bueno, Susan M. Kalergis, Alexis M. Soto-Rifo, Ricardo Valiente-Echeverría, Fernando Cortes, Claudia P. |
author_facet | Gaete-Argel, Aracelly Saavedra-Alarcón, Vicente Sauré, Denis Alonso-Palomares, Luis Acevedo, Mónica L. Alarcón, Marion Bueno, Susan M. Kalergis, Alexis M. Soto-Rifo, Ricardo Valiente-Echeverría, Fernando Cortes, Claudia P. |
author_sort | Gaete-Argel, Aracelly |
collection | PubMed |
description | INTRODUCTION: Booster doses of SARS-CoV-2 vaccines improve seroconversion rates in solid organ transplant recipients (SOTRs) but the impact of homologous and heterologous booster doses in neutralizing antibody (NAb) titers and their ability to interfere with the variant of concern Omicron are not well studied. METHODS: We designed a prospective, open-label, observational clinical cohort study. 45 participants received two doses of BNT162b2 or CoronaVac (21-day or 28-day intervals, respectively) followed by a first and second booster with BNT162b2 (5-month apart each) and we analyzed the neutralizing antibody titers against SARSCoV-2 D614G (B.1 lineage) and Omicron (BA.1 lineage). RESULTS: Our results show that SOTRs receiving an initial two-dose scheme of CoronaVac or BNT162b2 generate lower NAbs titers against the ancestral variant of SARS-CoV-2 when compared with healthy controls. Although these NAb titers were further decreased against the SARS-CoV-2 Omicron, a single BNT162b2 booster in both groups was sufficient to increase NAb titers against the variant of concern. More importantly, this effect was only observed in those participants responding to the first two shots but not in those not responding to the initial vaccination scheme. DISCUSSION: The data provided here demonstrate the importance of monitoring antibody responses in immunocompromised subjects when planning booster vaccination programs in this risk group. |
format | Online Article Text |
id | pubmed-10044136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100441362023-03-29 Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients Gaete-Argel, Aracelly Saavedra-Alarcón, Vicente Sauré, Denis Alonso-Palomares, Luis Acevedo, Mónica L. Alarcón, Marion Bueno, Susan M. Kalergis, Alexis M. Soto-Rifo, Ricardo Valiente-Echeverría, Fernando Cortes, Claudia P. Front Immunol Immunology INTRODUCTION: Booster doses of SARS-CoV-2 vaccines improve seroconversion rates in solid organ transplant recipients (SOTRs) but the impact of homologous and heterologous booster doses in neutralizing antibody (NAb) titers and their ability to interfere with the variant of concern Omicron are not well studied. METHODS: We designed a prospective, open-label, observational clinical cohort study. 45 participants received two doses of BNT162b2 or CoronaVac (21-day or 28-day intervals, respectively) followed by a first and second booster with BNT162b2 (5-month apart each) and we analyzed the neutralizing antibody titers against SARSCoV-2 D614G (B.1 lineage) and Omicron (BA.1 lineage). RESULTS: Our results show that SOTRs receiving an initial two-dose scheme of CoronaVac or BNT162b2 generate lower NAbs titers against the ancestral variant of SARS-CoV-2 when compared with healthy controls. Although these NAb titers were further decreased against the SARS-CoV-2 Omicron, a single BNT162b2 booster in both groups was sufficient to increase NAb titers against the variant of concern. More importantly, this effect was only observed in those participants responding to the first two shots but not in those not responding to the initial vaccination scheme. DISCUSSION: The data provided here demonstrate the importance of monitoring antibody responses in immunocompromised subjects when planning booster vaccination programs in this risk group. Frontiers Media S.A. 2023-03-13 /pmc/articles/PMC10044136/ /pubmed/36999018 http://dx.doi.org/10.3389/fimmu.2023.1135478 Text en Copyright © 2023 Gaete-Argel, Saavedra-Alarcón, Sauré, Alonso-Palomares, Acevedo, Alarcón, Bueno, Kalergis, Soto-Rifo, Valiente-Echeverría and Cortes https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Gaete-Argel, Aracelly Saavedra-Alarcón, Vicente Sauré, Denis Alonso-Palomares, Luis Acevedo, Mónica L. Alarcón, Marion Bueno, Susan M. Kalergis, Alexis M. Soto-Rifo, Ricardo Valiente-Echeverría, Fernando Cortes, Claudia P. Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients |
title | Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients |
title_full | Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients |
title_fullStr | Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients |
title_full_unstemmed | Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients |
title_short | Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients |
title_sort | impact of homologous and heterologous boosters in neutralizing antibodies titers against sars-cov-2 omicron in solid-organ transplant recipients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044136/ https://www.ncbi.nlm.nih.gov/pubmed/36999018 http://dx.doi.org/10.3389/fimmu.2023.1135478 |
work_keys_str_mv | AT gaeteargelaracelly impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT saavedraalarconvicente impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT sauredenis impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT alonsopalomaresluis impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT acevedomonical impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT alarconmarion impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT buenosusanm impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT kalergisalexism impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT sotoriforicardo impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT valienteecheverriafernando impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT cortesclaudiap impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients |